These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 15118273

  • 1. Transient hyperthyroidism after withdrawal of antithyroid drugs in patients with Graves' disease.
    Kubota S, Tamai H, Ohye H, Fukata S, Kuma K, Miyauchi A.
    Endocr J; 2004 Apr; 51(2):213-7. PubMed ID: 15118273
    [Abstract] [Full Text] [Related]

  • 2. The prevalence of transient thyrotoxicosis after antithyroid drug therapy in patients with Graves' disease.
    Kubota S, Takata K, Arishima T, Ohye H, Nishihara E, Kudo T, Ito M, Fukata S, Amino N, Miyauchi A.
    Thyroid; 2008 Jan; 18(1):63-6. PubMed ID: 18302519
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y, Takeoka K, Amino N.
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [Abstract] [Full Text] [Related]

  • 4. Two-day thionamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves' disease.
    Kubota S, Ohye H, Yano G, Nishihara E, Kudo T, Ito M, Fukata S, Amino N, Kuma K, Miyauchi A.
    Endocr J; 2006 Oct; 53(5):603-7. PubMed ID: 16896267
    [Abstract] [Full Text] [Related]

  • 5. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves' disease and painless thyroiditis.
    Kubota S, Amino N, Matsumoto Y, Ikeda N, Morita S, Kudo T, Ohye H, Nishihara E, Ito M, Fukata S, Miyauchi A.
    Thyroid; 2008 Mar; 18(3):283-7. PubMed ID: 18001177
    [Abstract] [Full Text] [Related]

  • 6. Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
    Žarković M, Wiersinga W, Perros P, Bartalena L, Donati S, Okosieme O, Morris D, Fichter N, Lareida J, Daumerie C, Burlacu MC, Kahaly GJ, Pitz S, Beleslin B, Ćirić J, Ayvaz G, Konuk O, Törüner FB, Salvi M, Covelli D, Curro N, Hegedüs L, Brix T, EUGOGO (European Group on Graves’ Orbitopathy).
    J Endocrinol Invest; 2021 Feb; 44(2):371-378. PubMed ID: 32524368
    [Abstract] [Full Text] [Related]

  • 7. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P, Berman DC, Andersen S, Bülow Pedersen I.
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [Abstract] [Full Text] [Related]

  • 8. Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves' Disease.
    Azizi F, Mehran L, Abdi H, Amouzegar A.
    J Clin Endocrinol Metab; 2024 Sep 16; 109(10):e1881-e1888. PubMed ID: 39018185
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study.
    Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M.
    J Endocrinol Invest; 2008 Oct 16; 31(10):866-72. PubMed ID: 19092290
    [Abstract] [Full Text] [Related]

  • 10. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D, de Nayer P, Bex M, Belgian Collaborative Study Group on Graves' Disease.
    Eur J Endocrinol; 2001 May 16; 144(5):475-83. PubMed ID: 11331213
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Relapse following antithyroid drug therapy for Graves' hyperthyroidism.
    Laurberg P, Krejbjerg A, Andersen SL.
    Curr Opin Endocrinol Diabetes Obes; 2014 Oct 16; 21(5):415-21. PubMed ID: 25111942
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
    Takata K, Amino N, Kubota S, Sasaki I, Nishihara E, Kudo T, Ito M, Fukata S, Miyauchi A.
    Clin Endocrinol (Oxf); 2010 Jun 16; 72(6):845-50. PubMed ID: 19912243
    [Abstract] [Full Text] [Related]

  • 15. When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?
    Park S, Song E, Oh HS, Kim M, Jeon MJ, Kim WG, Kim TY, Shong YK, Kim DM, Kim WB.
    Endocrine; 2019 Aug 16; 65(2):348-356. PubMed ID: 31236779
    [Abstract] [Full Text] [Related]

  • 16. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E, Gardini E, Minelli R, Bianconi L, Salvi M, Gavaruzzi G, Braverman LE.
    J Clin Endocrinol Metab; 1993 Apr 16; 76(4):928-32. PubMed ID: 7682562
    [Abstract] [Full Text] [Related]

  • 17. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
    Alexander EK, Larsen PR.
    J Clin Endocrinol Metab; 2002 Mar 16; 87(3):1073-7. PubMed ID: 11889166
    [Abstract] [Full Text] [Related]

  • 18. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease.
    Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R.
    J Clin Endocrinol Metab; 2001 Jul 16; 86(7):3016-21. PubMed ID: 11443161
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Painless thyroiditis mimicking relapse of hyperthyroidism during or after potassium iodide or thionamide therapy for Graves' disease resulting in remission.
    Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, Kitazono T.
    Endocr J; 2023 Feb 28; 70(2):207-222. PubMed ID: 36351595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.